RT Journal Article
SR Electronic
T1 A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19007146
DO 10.1101/19007146
A1 Stamate, Daniel
A1 Kim, Min
A1 Proitsi, Petroula
A1 Westwood, Sarah
A1 Baird, Alison
A1 Nevado-Holgado, Alejo
A1 Hye, Abdul
A1 Bos, Isabelle
A1 Vos, Stephanie
A1 Vandenberghe, Rik
A1 Teunissen, Charlotte E.
A1 Kate, Mara Ten
A1 Scheltens, Philip
A1 Gabel, Silvy
A1 Meersmans, Karen
A1 Blin, Olivier
A1 Richardson, Jill
A1 Roeck, Ellen De
A1 Engelborghs, Sebastiaan
A1 Sleegers, Kristel
A1 Bordet, Régis
A1 Rami, Lorena
A1 Kettunen, Petronella
A1 Tsolaki, Magda
A1 Verhey, Frans
A1 Alcolea, Daniel
A1 Lléo, Alberto
A1 Peyratout, Gwendoline
A1 Tainta, Mikel
A1 Johannsen, Peter
A1 Freund-Levi, Yvonne
A1 Frölich, Lutz
A1 Dobricic, Valerija
A1 Frisoni, Giovanni B
A1 Molinuevo, José L
A1 Wallin, Anders
A1 Popp, Julius
A1 Martinez-Lage, Pablo
A1 Bertram, Lars
A1 Blennow, Kaj
A1 Zetterberg, Henrik
A1 Streffer, Johannes
A1 Visser, Pieter J
A1 Lovestone, Simon
A1 Legido-Quigley, Cristina
YR 2019
UL http://medrxiv.org/content/early/2019/09/27/19007146.abstract
AB INTRODUCTION Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer’s Disease (AD). Here we set out to test the performance of metabolites in blood to categorise AD when compared to CSF biomarkers.METHODS This study analysed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV).RESULTS On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively.DISCUSSION This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disordersCompeting Interest StatementThe authors have declared no competing interest.Funding StatementIMI hasAuthor DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesOn request to the data repository’s